You are here

Category
Technology Name
Briefcase
Scientist
142
Monoclonal antibodies for Isoflavones, leukotrienes, biotin and human and veterinary drugs May be used for monitoring drug additives in food providing animals for veterinary use and for the food industry.   Biotin: §  116, 142 – Monoclonal antibody to Biotin            Description: Monoclonal...

Monoclonal antibodies for Isoflavones, leukotrienes, biotin and human and veterinary drugs

May be used for monitoring drug additives in food providing animals for veterinary use and for the food industry.

 

Biotin:

§  116, 142 – Monoclonal antibody to Biotin

           Description: Monoclonal antibodies raised against biotinylated BSA.

           Available clones: F1, F4.

Biotin, also known as vitamin H or coenzyme R, is a water-soluble B-vitamin (vitamin B7). Functions as coenzyme for carboxylase enzymes, involved in the synthesis of fatty acids, isoleucine, and valine, and in gluconeogenesis.

Reference: Bag?i H1, Kohen F, Kus?uoglu U, Bayer EA, Wilchek M. 1993. Monoclonal anti-biotin antibodies simulate avidin in the recognition of biotin. FEBS Lett. 322(1):47-50.

+
  • Dr. Fortune Kohen
237
236-237 - Diastereomer Lytic Peptides for Treatment of Solid Tumors and Metastasis Description: 15-mer (Leu-Lys-Dleu- Leu-Lys-Dlys-Leu-Dleu-Dlys-Lys-Leu-Leu-Dlys-Leu-Leu) and 15-mer Histidin (H-Leu-Lys-D-Leu- Leu-His-D-Lys-Leu-D-Leu-D-Lys-His-Leu-Leu-D-Lys-Leu-Leu-NH2) are membrane-active peptides...

236-237 - Diastereomer Lytic Peptides for Treatment of Solid Tumors and Metastasis

Description: 15-mer (Leu-Lys-Dleu- Leu-Lys-Dlys-Leu-Dleu-Dlys-Lys-Leu-Leu-Dlys-Leu-Leu) and 15-mer Histidin (H-Leu-Lys-D-Leu- Leu-His-D-Lys-Leu-D-Leu-D-Lys-His-Leu-Leu-D-Lys-Leu-Leu-NH2) are membrane-active peptides composed of both D- and L amino acids (diastereomers). These peptides have demonstrated potent anti-cancer and anti metastatic activities in several animal models including models for prostate and lung cancer. They were shown to successfully inhibit tumor growth when injected intratumorally or intraveneously. The 15-mer Histidine form shows reduced systemic toxicity.

References: Papo N, Braunstein A, Eshhar Z, Shai Y. 2004. Suppression of human prostate tumor growth in mice by a cytolytic D-, L-amino Acid Peptide: membrane lysis, increased necrosis, and inhibition of prostate-specific antigen secretion. Cancer Res. 64(16):5779-86.

Makovitzki A1, Fink A, Shai Y. 2009. Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides. Cancer Res. 69(8):3458-63.

+
  • Prof. Yechiel Shai
1655
Cellular senescence is a permanent cell cycle arrest induced by damage or stress applied on proliferating cells. In a cell autonomous manner, senescence is a potent barrier to tumorgenesis and contributes to the cytotoxicity of some anti-cancer drugs. However, with age senescence cells accumulate and...

Cellular senescence is a permanent cell cycle arrest induced by damage or stress applied on proliferating cells. In a cell autonomous manner, senescence is a potent barrier to tumorgenesis and contributes to the cytotoxicity of some anti-cancer drugs. However, with age senescence cells accumulate and promote a number of pathological conditions. Therefore the elimination of senescent cells is desired in order to prevent tumor- and inflammation- related pathologies and also to inhibit tissue ageing.
Today, our understanding of the mechanisms regulating the viability of senescent cells is limited. It has been suggested that senescent cells are resistant to apoptosis. Therefore, senescent cells elimination may be achieved by modifying the resistance to apoptosis of these cells.
Here the researches demonstrate the first feasible therapeutic approach that leads to eradication of senescent cells. Combination of direct induction of apoptosis in senescent cells with induction of cell death by pro-inflammatory repose induce by p21 knockdown will lead to reduction of viable senescent cells.

Applications


  • A therapeutic impact on inflammatory and fibrotic disease
  • Therapy for age-related disease such as type 2 diabetes, Alzheimer’s disease, Atherosclerosis, cataracts, Chronic obstructive pulmonary disease (COPD), and Osteoporosis

Advantages


  • Effective elimination of senescent cells- removal of senescent cells can prevent or delay tissue dysfunction and extend health span
  • Does not damage normal cells even at high concentrations

Technology's Essence


Researches demonstrated that the anti-apoptotic proteins Bcl-xL and Bcl-w level were elevated in senescence cells of both human and mouse origin. A subsequent study, in which Bcl-xL and Bcl-w were knocked down by siRNA, revealed that a combined knock down of Bcl-xL and Bcl-w had synergic effect, resulting in reduction of 50% in cell viability. Thus the increased level of anti-apoptotic proteins Bcl-xL and Bcl-w may account for the apoptotic resistance of senescent cells. p21 knockdown induced pro-inflammatory response and cell death in senescent cells.
Overall, the researchers show that combined inhibition of the anti-apoptotic proteins Bcl-xL and Bcl-w allows specific elimination of senescent cells and might be used to treat diseases where senescent cells are present. The researchers also found that the same effect might be achieved by reducing the expression of p21 in senescent cells. Integrating both approaches propose a more effective therapy.

+
  • Prof. Valery Krizhanovsky
1498
MicroRNAs as potential biomarkers for ALS.Amyotrophic Lateral Sclerosis (ALS) is a devastating disease that progressively destroys motor neurons in the brain and the spinal cord, eventually causing paralysis and death. Currently, there are approximately 25,000 patients with ALS in the USA, with a...

MicroRNAs as potential biomarkers for ALS.
Amyotrophic Lateral Sclerosis (ALS) is a devastating disease that progressively destroys motor neurons in the brain and the spinal cord, eventually causing paralysis and death. Currently, there are approximately 25,000 patients with ALS in the USA, with a median age of onset of 55 years. Approximately 5–10% of patients with ALS have a family history, and these patients most frequently inherit the disease in an autosomal dominant manner. Family-based linkage studies have led to the identification of several genes for familial ALS. However these findings only explain a small fraction of all ALS cases. The majority of ALS cases have no obvious family history and are referred to as sporadic ALS. At present, there is no effective therapy for the disease and patients usually die within 2-5 years after the onset of symptoms. Thus, there is an urgent need for biomarkers that could substantially aid early diagnosis of ALS and will help in designing decisive clinical trials of new drugs. The present technology provides specific microRNAs that can serve as potential biomarkers for ALS.

Applications


  • Unique patterns of microRNA expression profile in the cerebrospinal fluid of ALS patients could be useful as molecular biomarkers for disease diagnosis and eventually prediction of therapeutic responses.
  • The suggested ALS biomarkers may be employed in drug development studies.

 


Advantages


  •  MicroRNAs can be precisely quantified using qRT-PCR that provides exceptionally high sensitivity and specificity of detection.
  • The small size of microRNAs offers a unique advantage since they are more stable and less prone to enzymatic degradation, and are therefore amenable to an accurate assessment of their expression levels.

Technology's Essence


MicroRNAs (miRNAs) are endogenous small noncoding RNAs that negatively regulate gene expression in a posttranscriptional fashion and contribute to a wide variety of biological processes. miRNAs play important roles in the development of the central nervous system and their involvement in neurodegenerative diseases such as Parkinson's disease and Alzheimer’s disease has been recently established. The outlined technology describes specific miRNAs that are enriched in motor neurons and are significantly downregulated in mouse models of hereditary motor neuron disease (SOD1G93A and SMN1). These miRNAs may serve as putative biomarkers for motor neuron diseases such as ALS by measurement of their expression levels in cerebrospinal fluid samples collected from affected individuals.

+
  • Dr. Eran Hornstein
1431
A method to monitor the amount of milk consumed by the baby during breastfeeding.Breastfeeding has been shown to have important health advantages for both baby and mother. A few months of exclusive breastfeeding has been shown to reduce the risk of infant gastro-intestinal problems, respiratory,...

A method to monitor the amount of milk consumed by the baby during breastfeeding.

Breastfeeding has been shown to have important health advantages for both baby and mother. A few months of exclusive breastfeeding has been shown to reduce the risk of infant gastro-intestinal problems, respiratory, urinary tract and ear infections. Furthermore, adults who were breastfed at infancy have a lower propensity for obesity, high cholesterol levels and high blood pressure – all risk factors for heart disease. Despite these advantages less than 50% continue breastfeeding beyond 4 weeks. The most common reason given for not breastfeeding or breastfeeding less than three months is ‘not enough milk’. The perception that milk production is insufficient however is subjective. At present, the only method to monitor the amount of milk a baby eats is by weighing the baby before and after feeding. The current technology can monitor amount and quality of milk during breastfeeding.

Applications


Monitoring of the amount of milk given while breastfeeding

Advantages


·        This method allows measuring both milk quantity and quality

  • Encourage infant breastfeeding.
  • Measurement of capacitance with no electrical contact between the electrodes and the body

Technology's Essence


The outlined technology consists of monitoring the amount of milk consumed by a baby during breastfeeding by measuring the capacitance between electrodes placed on the breast (but not in electrical contact with them) during feeding. It is sensitive to the amount, dielectric properties and distribution of matter in the immediate neighborhood of the capacitor plates. When placed on the breasts the capacitance is affected by the amount and properties of materials between plates, including milk content and constitution. Thus, if the amount of milk in the breast is reduced during breastfeeding the capacitance changes accordingly.

+
  • Ph.D. Ruti Kapon
1698
GD is an inherited metabolic disorder, affecting about 1 in 20,000 births. GD is divided into three clinical subtypes: type 1 is the most common and is characterized by bruising, fatigue, anemia, low blood platelets, and enlargement of the liver and spleen. Types 2 and 3, also called neuronopathic GD (...

GD is an inherited metabolic disorder, affecting about 1 in 20,000 births. GD is divided into three clinical subtypes: type 1 is the most common and is characterized by bruising, fatigue, anemia, low blood platelets, and enlargement of the liver and spleen. Types 2 and 3, also called neuronopathic GD (nGD), affect 4% of GD patients and additionally include neurological symptoms. Type 1 patients can have a normal life expectancy if treated whereas type 2/3 patients do not survive to reach adulthood. Moreover, GD carriers, approximately 1% of the population, are in a major risk of developing Parkinson’s disease. Current therapies suffer from severe drawbacks in the treatment of type 1 GD and no therapy exists that effectively treat nGD. The present technology offers a novel therapeutic target for the treatment of Gaucher's disease (GD) which addresses also the neurological symptoms.

Applications


  • Alternative treatment for type 1 GD
  • First line therapy for nGD

Advantages


  • A novel therapy for nGD which has no treatment for the present.
  • A novel therapeutic approach for GD type 1, via a previously unknown molecular mechanism.
  • Allows the development of an orally administered treatment, far more convenient for the patients than the existing treatments.
  • Reduced costs compared to the existing therapies of ERP or BMT

Technology's Essence


The proposed technology is based on the discovery that RIP3 is a key player in the manifestation of GD and that inhibiting RIP3 activity is effectively ameliorating the symptoms of GD not only in the less severe type 1 but also in the neuropathic form of the disease, types 2 and 3. nGD is associated with a massive neuronal loss and elevated RIP3 levels. Inhibition of RIP3 in a mouse model of nGD resulted in a dramatic attenuation of disease signs: drastic extension of life span, no weight loss, improvements in motor coordination, reduced neuroinflammation and improved liver and spleen injuries.

+
  • Prof. Anthony H. Futerman
1446
Peptide sequences for efficient inhibition of nuclear translocation of proteins. The ability to regulate cellular localization of a biological component is important for many functions such as gene therapy, protection from toxic chemicals, transport of anti-cancer agents, and possibly preventing...

Peptide sequences for efficient inhibition of nuclear translocation of proteins.

The ability to regulate cellular localization of a biological component is important for many functions such as gene therapy, protection from toxic chemicals, transport of anti-cancer agents, and possibly preventing nuclear translocation of oncogenes. To ensure accurate cellular functioning, the spatial distribution of proteins needs to be delicately regulated and coordinated. This is particularly apparent in many signaling proteins that dynamically and rapidly change their localization upon extracellular stimulation. The present invention provides peptides that may be used to regulate the nuclear translocation of proteins that endogenously comprise such nuclear translocation signals.

Applications


  • Inhibition of translocation of endogenous oncogenes and thereby the transcription they induce.

Advantages


  • Regulation of the level of nuclear targeting activity by selection of different amino acids in the peptide sequences.

  • Peptides can be modified in order to make them more stable in the body.
  • Modulation of the nuclear activities of proteins without harming their cytoplasmic activities.

Technology's Essence


The current invention identifies a 3-amino acid domain (Ser-Pro-Ser, SPS), which is a nuclear translocation signal present in signaling proteins such as extracellular signal-regulated kinase (ERK2) protein, SMAD3 and mitogen-activated protein kinase 1 (MEK1). SPS participates in nuclear translocation upon extracellular stimulation. Since several of these proteins are involved in the regulation of cellular proliferation and oncogenic transformation, the SPS domain can compete with the translocation machinery and therefore prevent the translocation of the proteins into the nucleus. As was shown in animal models, inhibiting this mechanism has an advantage over other ways of inhibition as it doesn’t lead to a negative feedback loop which may enhance the production of the protein.

+
  • Prof. Rony Seger
1642
A potential target for anticancer drug design.Cancer is the second leading cause of death in the US, accounting for roughly 23% of all deaths (as of 2008), and with estimated cost of care of $157 billion (as of 2010). Despite major advances in the management of cancer, most types of solid tumors remain...

A potential target for anticancer drug design.
Cancer is the second leading cause of death in the US, accounting for roughly 23% of all deaths (as of 2008), and with estimated cost of care of $157 billion (as of 2010). Despite major advances in the management of cancer, most types of solid tumors remain resistant to conventional treatment modalities. The local microenvironment, or niche, of a cancer cell plays important roles in cancer development. A major component of the niche is the extracellular matrix (ECM), a rich mesh of fibrous proteins surrounding cells that has been shown to exert a protective and supporting effect on cancer progression. Therefore, targeting the ECM represents a novel avenue for rational anticancer drug design. The current technology allows for specific targeting of an enzyme that takes part in ECM assembly and maintenance, and may provide a novel means for combating cancer progression and metastasis emergence.

Applications


  • Inhibitory antibodies to block QSOX1 catalytic activity in ECM as means to combat cancer progression and metastatic disease.
  • ]QSOX1 inhibition may also be utilized to treat lamin-associated disease.

Advantages


  • Since QSOX1 functions outside cells it would be accessible to antibodies that are not readily taken up by cells.
  • Since the microenvironment confers anticancer therapy resistance, a treatment that specifically targets the stromal cells may be synergistically combined with existing therapeutic modalities.

Technology's Essence


A team of researchers at the Weizmann Institute have that a secreted disulfide bond catalyst known as Quiescin sulfhydryl oxidase 1 (QSOX1) is required for proper assembly of the ECM. The main substrates of QSOX1 within the ECM are laminins. Thus, cells lacking QSOX1 show poor incorporation of laminin into the ECM mesh, resulting in decreased cell adherence and perturbed cell migration. Notably, in some cancer types such as pancreatic and breast cancers, QSOX1 and the ECM components it produces are over-expressed. This suggests that modulation of QSOX1 activity may provide a novel means to combating cancer and metastasis. Treatment of cancer cells with a monoclonal QSOX1-targeting antibody effectively blocked cell migration and provides a novel strategy for cancer treatment by QSOX1 inhibition.

+
  • Prof. Deborah Fass

Pages